Merck’s Lipfendra is the first FDA-approved pill in the class of cholesterol-lowering drugs called PCSK9 inhibitors. While peptides are typically injected, Lipfendra is a macrocyclic peptide designed for formulation as an oral drug.
GSK said the mixed Phase 3 results for camlipixant mean this pill “is unlikely to transform patient care” in recurrent chronic cough. GSK is stopping work in this indication, a setback to a program once hoped to yield a new blockbuster product for the company’s respiratory drug portfolio.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Eli Lilly’s AtaiBeckley acquisition marks a dozen M&A deals for the pharma company so far this year. AtaiBeckley’s lead program is an intranasally administered psychedelic drug in pivotal testing for treatment-resistant depression.
Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of breast cancer that do not harbor a certain mutation. The intravenously infused medicine is first in a new drug class that addresses a pathway associated with many cancers.
The FDA now treats continuous, real-time data sharing as a regulatory direction of travel rather than a theoretical future. The neurology field should pay close attention.
Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a rare autoimmune condition where Spero aims to offer advantages over the Amgen drug that is currently the only approved treatment.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
GSK drug Jemperli met the main goal of a pivotal Phase 2 test in patients with a rare type of rectal cancer, paving the way for regulatory submissions. This antibody drug has already received a voucher to speed up its review under a new FDA pilot program.
Healthcare cybersecurity is no longer just about protecting electronic health records. It is increasingly about protecting the research, algorithms, clinical data, and intellectual property that drive the next generation of medicine.
Focusing on two gene variants obscures the more complex gene relationships that drive obesity. Here’s what we miss if we only focus on one gene variant at a time.
AstraZeneca is getting rights to a Sino Biopharmaceutical drug that offers a dual mechanism to treat chronic obstructive pulmonary disease, or COPD. It’s the same approach as an FDA-approved drug that Merck acquired last year in a multi-billion dollar deal.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
A Bausch + Lomb drug from a 2025 acquisition missed primary and secondary goals of a Phase 2 test in glaucoma. Bausch now plans to develop this drug for geographic atrophy, aiming to succeed where Allergan, now an AbbVie subsidiary, fell short in the clinic.
AstraZeneca and Ionis Pharmaceuticals drug eplontersen, brand name Wainua, failed a Phase 3 test in cardiomyopathy caused by transthyretin amyloidosis. More details will be shared at a medical conference next month, but it appears the RNA therapy’s slim hopes now ride on a subgroup analysis.
FDA approval of Vera Therapeutics’ Trutakna makes it first in a new class of medicines designed to block two targets to treat immunoglobulin A nephropathy, an autoimmune disease that can progress to end-stage renal failure. Competition looms from Vertex Pharmaceuticals, on track to receive a November regulatory decision for a drug designed to block the same two proteins.
Many startups and established companies focused on drug testing on human data in preclinical studies have been boosted by FDA's move away from reliance on animal testing towards organoid, organ-on-a-chip, and other in silico technologies. A Connecticut startup believes whole-organ testing should be an essential part of this mix.
Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals values the company at about $10 billion. Crinetics’s Palsonify could become a new standard of care therapy for acromegaly and the biotech also brings other drugs in various stages of development for endocrine disorders, a new therapeutic area for Vertex.